Skip to main content
PMC home page
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2023 Jan 18;14:1078705. doi: 10.3389/fimmu.2023.1078705

Knowledge landscape of tumor-associated macrophage research: A bibliometric and visual analysis

Feng Zhou 1,2,3,4, Yang Liu 1,2,3,4, Cong Liu 1,2,3,4, Fangfei Wang 1,2,3,4, Jianxiang Peng 1,2,3,4, Yong Xie 1,2,3,4,*, Xiaojiang Zhou 1,2,3,4,*
PMCID: PMC9890162  PMID: 36742323

Abstract

Background and aims

Tumor-associated macrophage (TAM) is a highly abundant immune population in tumor microenvironment, which plays an important role in tumor growth and progression. The aim of our study was to explore the development trends and research hotspots of TAM by bibliometric method.

Methods

The publications related to TAM were obtained from the Web of Science Core Collection database. Bibliometric analysis and visualization were conducted using VOSviewer, CiteSpace and R software.

Results

A total of 6,405 articles published between 2001 and 2021 were included. The United States and China received the most citations, whereas the University of Milan, the university of California San Francisco and Sun Yat-sen University were the main research institutions. Mantovani, Alberto from Humanitas University was the most productive authors with the most citations. Cancer Research published the most articles and received the most co-citations. Activation, angiogenesis, breast cancer, NF-κB and endothelial growth factor were important keywords in TAM research. Among them, PD-1/L1, nanoparticle, PI3Kγ, resistance and immune microenvironment have become the focus of attention in more recent research.

Conclusions

The research on TAM is rapidly evolving with active cooperation worldwide. Anticancer therapy targeting TAM is emerging and promising area of future research, especially in translational application. This may provide guidance and new insights for further research in the field of TAM.

Keywords: tumor-associated macrophage, cancer, bibliometrics, visualization, hotspots

Introduction

Macrophages has long been considered to be an evolutionarily ancient cell type involved in tissue homeostasis and immune defense. Recently, macrophages were discovered to regulate a variety of diseases depending on the surrounding tissue microenvironment, especially for cancer (1–3). Tumor-associated macrophage (TAM) is a highly abundant immune population in tumors, which plays an important role in cancer progression, metastasis and treatment resistance.

The ability of macrophages to adapt to subtle changes in external stimuli results in the diversity of TAM between different types of cancer or within the same tumor. Macrophages are generally divided into classically activated M1 phenotypes and alternately activated M2 phenotypes to reflect the Th1/Th2 immune response. Although TAM often shows more similar patterns to M2- polarized macrophages that suppresses immune responses and promotes tumor progression, the simplified M1/M2 definition might not be sufficient to cover the full complexity of TAMs (4). In fact, TAM rarely completely follow the true M1 and M2 phenotypes, and even some macrophages can share both M1 and M2 signatures (5–7). In addition, the cell subsets do not exist at a steady stage and changes as the tumor progresses. Each population has a unique landscape based on the type, stage and immune composition of the infiltrated tumors. The plasticity and heterogeneity allow TAM to promote or suppress tumor growth and progression through multiple pathways. Therefore, there is great significance to quantitatively evaluate the research status, focus area and development trend of TAM.

Bibliometrics is an interdisciplinary science that provides a comprehensive and objective assessment of knowledge carriers by mathematics and statistics (8–10). The bibliographic analysis helps scholars understand the development of specific topic and reveals the evolution trend of this field. This study aimed to explore the landscape of tumor-associated macrophages, hoping to provide new clues and ideas for future research in the field of TAM.

Methods

Search strategies

Scientific output data was extracted from the Web of Science Core Collection (WoSCC) database, which is one of the most widely used source for academic and bibliometric analysis. The search formula was presented as follows: TS = (“tumor associated macrophage*”) OR (“tumor-associated macrophage*”) OR (“tumour associated macrophage*”) OR (“tumour-associated macrophage*”) OR (“cancer associated macrophage*”) OR (“cancer-associated macrophage*”). The publication period was limited to between 2001 and 2021, and the publication type was limited to original articles written in English. Moreover, we also used broader terms as a benchmark dataset to better evaluate the overall trend of immune cell research in cancer such as “tumor OR tumour OR cancer” and “T cell OR macrophage OR neutrophil*”. The literature search and data collection were performed independently by two researchers to ensure the reliability of the results.

Data collection

Original data was extracted from selected publications, including titles, abstracts, authors, affiliations, countries/regions, journals, publication years, references and keywords. The H-index of scholars, impact factor (IF) and Journal citation reports (JCR) division of journals were obtained from the Web of Science. Productivity of activities is measured by the number of citations. Overlapping items were merged into a single element and misspelled words were corrected artificially. The cleaned data were exported for further analysis.

Bibliometric analysis

Bibliometric indicators are used to quantitatively describe and evaluate the characteristics of literature and its trends. We used R software to conduct Lotka’s Law analysis (11). VOSviewer is a bibliometric tool for developing scientometric network and knowledge visualization (12). The network graph generated by VOSviewer displays the size of nodes according to the number of publications, where closely related nodes are grouped into the same cluster. The connection indicates the association of different nodes, and the thickness of the connection depends on the strength of the association. Centrality is used to measure the importance of a node’s location in the network, and nodes with centrality greater than 0.1 are generally considered as critical nodes. CiteSapce software provides new angle for the bursts of research hotspots in the field of TAM (13).

Results

A total of 9,694 literatures were published in the field between 2001 and 2021. According to the exclusion criteria, we finally included 6,405 eligible original articles in our study. The specific flow diagram was illustrated in Figure 1 .

Figure 1.

Figure 1

Open in a new tab

Flowchart of literature screening.

Growth trend of publication

The overall growth trend of immune cell research in cancer were showed in Figure 2A . Although T cell is the most heavily studied immune population, the field of macrophage showed similar increase rate of up to three times. For tumor-associated macrophage research, the number of articles published exhibited a steady increase from 2001 to 2021 ( Figure 2B ). The output of publications from 2001 to 2008 was low, with less than 100 articles per year. With the fast increase in the number of annual publications, there were 6,028 articles on TAM published between 2009 and 2021, accounting for 94.1% in the past two decades. These findings indicated that TAM has gained great interest and entered the phase of rapid development.

Figure 2.

Figure 2

Open in a new tab

(A) The overall growth trend of annual immune cell research in cancer. (B) Annual and cumulative growth trend of TAM publications.

Distribution of countries/regions and institutions

The publications on TAM were conducted by 5,294 institutions in 99 countries/regions ( Table 1 ). The United States received the highest citations (N=123799), followed by China (N=71126) and Italy (N=28368). Annual citations per publication peaked in the middle of the study period in most countries/regions, especially for Italy ( Figure 3A ). Although China carried out the most publications, the average number of citations is lower than other countries/regions. The bibliometric map revealed the tight communications between countries/regions ( Figure 3B ). Intense collaborations between countries/regions resulted in thicker connecting lines between nodes. Of them, the centrality of the United States is as high as 0.37, suggesting that it plays a strong bridge role between the cooperations. In addition, China, Italy, Germany, Japan and United Kingdom are also important nodes among clusters, with centrality greater than 0.1.

Table 1.

The top 10 countries/regions and institutions that have contributed to publications on tumor-associated macrophage research.

Country Centrality Count Citation Institution Centrality Count Citation
United States 0.37 1947 123799 Univ Milan 0.12 67 12892
China 0.13 2157 71126 Univ Calif San Francisco 0.02 55 8971
Italy 0.14 369 28368 Sun Yat Sen Univ 0.05 165 7727
Germany 0.20 469 25772 Univ Texas Md Anderson Canc Ctr 0.12 107 6741
Japan 0.17 599 22314 Harvard Univ 0.08 55 6529
United Kingdom 0.15 253 15545 Mem Sloan Kettering Canc Ctr 0.11 73 6436
France 0.05 199 13833 Fudan Univ 0.01 152 6425
Switzerland 0.06 135 11200 Shanghai Jiao Tong Univ 0.07 149 6397
Netherlands 0.06 170 10305 Stanford Univ 0.04 74 6335
Spain 0.04 157 9849 Massachusetts Gen Hosp 0.04 55 5708
Open in a new tab

Figure 3.

Figure 3

Open in a new tab

(A) Scientific productivity of authors based on Lotka’s Law. (B) The network map of authors on tumor-associated macrophage research.

The 5,294 institutions constituted seven main clusters ( Figure 3C ). The University of Milan, the university of California San Francisco and Sun Yat-sen University were the most productive institutions, with centrality ranged from 0.02 to 0.12. The University of Texas MD Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center also had a centrality of more than 0.1 and belonged to a key node of the network.

Author and co-author analysis

There were 41,399 authors involved in the study of tumor-associated macrophages. Scientific productivity based on Lotka’s law shows that 73.1% of authors contributed only one publication ( Figure 4A ). Mantovani, Alberto from Humanitas University received the most citations (N=10675) with the most publications ( Table 2 ). The next productive authors were Sica, Antonio from University of Eastern Piedmont Amedeo Avogadro (N=9344) and Coussens, Lisa M from University of California San Francisco (N=5745). There were active collaborations among the author clusters of seven different colors ( Figure 4B ). A certain degree of collaborations existed between two linked nodes in different clusters, such as Pollard, Jeffrey W and De Palma, Michele.

Figure 4.

Figure 4

Open in a new tab

(A) Annual citations per publication for the top 10 countries. The network map of countries/regions (B) and institutions (C) on tumor-associated macrophage research.

Table 2.

The top 10 productive authors and cited authors in the field of tumor-associated macrophages.

Authors Count H-index Cited author Count H-index
Mantovani, Alberto 39 182 Mantovani, Alberto 10675 182
Komohara, Yoshihiro 36 45 Sica, Antonio 9344 72
Fujiwara, Yukio 33 32 Coussens, Lisa M 5745 81
Bruene, Bernhard 30 73 DeNardo, David G 4519 40
Weigert, Andreas 27 40 Lawrence, Toby 3909 40
Sica, Antonio 26 72 Ruffell, brian 3848 29
Aiba, Setsuya 24 40 Van Ginderachter, Jo A 3702 62
Takeya, Motohiro 23 62 Weissleder, Ralph 3337 168
Van Ginderachter, Jo A 22 45 Pollard, Jeffrey W 3246 30
Van Ginderachter, Jo A 22 62 Pittet, Mikael 3187 72
Open in a new tab

Journals and cited academic journals

A total of 1,201 journals were identified in this research field. The journal with the most publications was Cancer Research (N=173), followed by Plos One (N=152) and Oncotarget (N=148). Among the top ten journals related to TAM, 7 journals have an impact factor greater than 5, and 5 journals were at the Q1 JCR division ( Table 3 ). At the same time, Cancer Research generated the most co-citations (N=18479). Figure 5A showed Scientific Reports, Cancers and Frontiers in Oncology were relatively new to this field, but developed rapidly.

Table 3.

The top 10 journals and cited journals related to tumor associated macrophages.

Journal Count IF (2021) JCR (2021) Cited journal Citation IF (2021) JCR (2021)
Cancer Research 173 13.312 Q1 Cancer Research 18479 13.312 Q1
Plos One 152 3.752 Q2 Cancer Cell 9039 38.585 Q1
Oncotarget 148 – – Clinical Cancer Research 8991 13.801 Q1
Oncoimmunology 110 7.723 Q1 Proceedings of the National Academy of Sciences of the United States of America 8035 12.779 Q1
Scientific Reports 104 4.996 Q2 Plos One 7910 3.752 Q2
Clinical Cancer Research 95 13.801 Q1 Journal of Experimental Medicine 7358 17.579 Q1
Cancers 90 6.575 Q1 Journal of Immunology 8030 5.426 Q2
Cancer Letters 86 9.756 Q1 Journal of Clinical Investigation 6982 19.456 Q1
Journal of Immunology 85 5.426 Q2 Blood 6437 25.476 Q1
Frontiers in Oncology 83 5.738 Q2 Nature Communication 3943 17.694 Q1
Open in a new tab

Figure 5.

Figure 5

Open in a new tab

(A) Annual number of publications for the top 10 journals. (B) The network map of journals on tumor-associated macrophage research.

The cited journals network indicated the association between two journals. Journals are divided into four clusters, and the size of nodes represented the number of co-citations ( Figure 5B ). There was similar theme between journals of the same color, especially for red cluster.

Keywords co-occurrence, clusters and bursts

Keywords were extracted from the 6,405 published articles. As shown in Table 4 , NF-κB (N=336), endothelial growth factor (N=204) and PD-L1 (N=170) were the most commonly involved molecules. Activation (N=1002), polarization (N=903) and angiogenesis (N=806) appeared more frequently for pathological processes. As for specific diseases, breast cancer (N=840), colorectal cancer (N=287) and lung cancer (N=251) received the most attention.

Table 4.

The top 10 molecules, pathological process and disease related to tumor associated macrophages research.

Molecules Count Pathological processes Count Diseases Count
NF-Kappa B 336 Activation 1002 Breast cancer 840
Endothelial growth factor 204 Polarization 903 Colorectal cancer 287
PD-L1 170 Angiogenesis 806 Lung cancer 251
CD163 149 Infiltration 341 Hepatocellular carcinoma 240
Colony stimulating factor 146 Differentiation 291 Glioblastoma 164
INF-gamma 141 Proliferation 255 Gastric cancer 164
TGF-β 118 Epithelial mesenchymal transition 219 Ovarian cancer 148
STAT3 116 Apoptosis 206 Pancreatic cancer 141
Nitric Oxide 107 Metabolism 99 Melanoma 137
CD68 93 Recruitment 97 Prostate cancer 136
Open in a new tab

Clustering keywords help to identify the distribution of research content on a specific topic ( Figure 6 ). The largest blue cluster consisted of keywords was associated with the pathological processes and molecules of macrophages, including angiogenesis, NF-Kappa B and oxidative stress. Red cluster involved the cancer treatment, including immunotherapy, resistance and nanoparticle. Yellow cluster mainly explored the factors associated with tumor prognosis.

Figure 6.

Figure 6

Open in a new tab

The network map of keywords on tumor-associated macrophage research.

A visual map was constructed to show the trend of keywords bursts, where the red part represented the duration of citation burst ( Figure 7 ). The early burst keywords included angiogenesis, epithelial growth factor, and colony stimulating factor. Citation bursts in the middle period (2011-2016) were significantly attenuated with a decrease in hotspot keywords such as NF-κB, Hodgkin lymphoma and scavenger receptor. In recent years (2018-2020), the treatment of cancer received increasing attention from researchers. PD-1/L1, PI3Kγ, resistance, nanoparticle and immune microenvironment has become the focus of attention of current research.

Figure 7.

Figure 7

Open in a new tab

The top 50 keywords with the strongest citation bursts on tumor-associated macrophage research.

Discussion

Tumor-associated macrophage is an important part of the tumor microenvironment and interacts with cancer cells to maintain the most of characteristics of tumors. The diversity of TAM forms a complex communication network between cancer and immune cells (14). In this study, we extracted TAM studies from public databases for bibliometric analysis to identify its hotspots and development trends. The increasing trend in annual publication volume demonstrated the significant potential of TAM in cancers.

The United States and China were the countries with the most citations. The distribution of institutions is consistent with countries/regions based on geographical location. However, the average citations for most countries/regions and institutions did not correspond well to the number of publications in this field. More robust efforts may be required to deeply clarify the role and mechanism of TAM in tumor. Meanwhile, the United States achieves a maximum level of cooperation in TAM research with a centrality of 0.37. Compared with other countries, it constitutes several cooperative subnetworks to better promote the development of the field, such as the University of Texas MD Anderson Cancer Center, Memorial Sloan-Kettering Cancer Center and University of Chicago.

Regarding the productivity of authors, Alberto Mantovani received the most citations in the TAM field. Mantovani mainly focused on the regulatory effect of chemokines on TAM (15–17) and some related anticancer drugs such as trabectedin (18, 19). Given the limitation of the binary M1-M2 classification of macrophage, Mantovani also attempted to divide macrophages into additional subsets (M2a, M2b and M2c) (20) or used looser terms (M1-like and M2-like) (21). Besides the collaborations with Mantovani, Antonio Sica made efforts to link inflammatory reaction to cancer through NF-κB (22–24). Coussens’s group from University of California San Francisco focused more on the immune cell crosstalk in breast cancer (25–27).

Cancer research published the most articles and received the highest number of co-citations. Scientific Reports, Cancers and Frontiers in Oncology were emerging journals spreading macrophage research. Papers published in highly cited journals such as Nature, Blood and Cell were more likely to be reviewed by scholars and have more access to citations.

The clustering analysis of keywords indicated that TAM research ranged from the biological properties of macrophages to the targeted therapy of cancer. TAM is highly related to specific pathological context, and its complex mechanism in tumors has attracted extensive attention. Angiogenesis is the initial research focus, which provides basic condition for tumor growth and dissemination. Angiogenesis is the initial research focus, which provides basic condition for tumor progression. Studies have shown that TAM can promote angiogenesis through the release of cytokines, growth factors and matrix metalloproteinases or the expression of TIE2 receptors (28–32). NF-κB is considered to be a molecular link between the inflammation and cancer. In the middle period, it gradually presented the highest citation burst strength. NF-κB activation in macrophages is essential for tumor growth. Inhibition of IKKβ leads to a significant reduction in tumor onset and load of several inflammation-induced cancer models (33–35). However, TAM often shows alternative immunosuppressive M2-like phenotype, which is not easily reconciled with the proinflammatory function of NF-κB in TAM. The scavenger receptor MARCO expressed on the surface of macrophages is able to regulate macrophage polarization and enhance tumor killing (36, 37).

Recently, anticancer therapy targeting TAM has generated the most research enthusiasm. Immunosuppression microenvironment limits the efficacy of checkpoint block and adoptive cell therapy, particularly in solid tumors (38). TAMs can suppress immunotherapy efficacy by inhibiting T-cell activity and enhancing the expression of PD-L1 in the TME. In addition to inhibiting T cell activation, a study from Sydney et al. showed that immune checkpoint inhibitor PD-1/L1 also inhibited TAM phagocytosis, which may be associated with M2 polarization (39). In-depth inquiry of PD-1/L1 expanded the knowledge of PD-1/L1 from its role in T cells to many other cell types, including macrophages. PI3K/Akt is also an important signaling pathway participating in macrophages survival, proliferation and cytoskeleton rearrangement. PI3K induces TAMs into M2-like phenotype and is closely correlated with poor clinical outcomes of cancers (40). Inhibition of PI3Kγ make tumors sensitive to immune checkpoint inhibitors by reprogramming TAM, demonstrating the importance of macrophage-mediated immune microenvironment for optimal immunotherapy efficacy (41–43). CSF-1R expressed on TAMs is involved in the activation of PI3K signaling pathway, and regulate the immune inhibition in macrophages. Blockade of CSF1 has been shown to deplete TAM and prevent TAM recruitment to the tumor (44, 45). Targeting TAM can play its unique regulatory function in promoting the antitumor effects of current immunotherapy.

Due to the unique biophysical properties, nanoparticles show greater advantages and potentials in cancer treatment. Compared with traditional drugs, nanoparticles can extend retention time and achieve targeted delivery with a decreased toxicity. Some studies have reported that nanoparticles specifically enhance anticancer immune responses by targeting TAM (46–50). The rich blood circulation and strong phagocytosis ability also make macrophages themselves become the optimal carrier of drug delivery. TAM allows the delivery of nanotherapeutic drugs to tumor cells and alters the spatial diffusion of drugs within the tumor (51, 52). Imaging the response between tumors and nanomaterials provide a reliable basis for the development of highly effective targeted therapies.

The bibliometric study reflected the development trend and research hotspots in this field to a certain extent. At the same time, this study has several limitations. The included literatures were collected from WOSCC database, which caused the omission of some information. Furthermore, there were potential biases in bibliometric method based on natural language processing. Excessive adjustments for inaccurate elements may reduce the credibility of the results.

In conclusion, the research on TAM is rapidly evolving with active cooperation worldwide. And anticancer therapy targeting TAM is emerging and promising area of future research, especially in translational application. This may provide guidance and new insights for further research in the field of TAM.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Author contributions

XZ and YX designed the study. YL, CL and FW conducted data extraction. FZ, YX and JP performed data analysis. FZ drafted the manuscript. XZ interpreted the data and revised the manuscript. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1. Pittet MJ, Michielin O, Migliorini D. Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol (2022) 19(6):402–21. doi:  10.1038/s41571-022-00620-6 [DOI] [PubMed] [Google Scholar]
  • 2. Mehla K, Singh PK. Metabolic regulation of macrophage polarization in cancer. Trends Cancer (2019) 5(12):822–34. doi:  10.1016/j.trecan.2019.10.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature (2013) 496(7446):445–55. doi:  10.1038/nature12034 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Christofides A, Strauss L, Yeo A, Cao C, Charest A, Boussiotis VA. The complex role of tumor-infiltrating macrophages. Nat Immunol (2022) 23(8):1148–56. doi:  10.1038/s41590-022-01267-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol (2020) 15:123–47. doi:  10.1146/annurev-pathmechdis-012418-012718 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Yang M, McKay D, Pollard JW, Lewis CE. Diverse functions of macrophages in different tumor microenvironments. Cancer Res (2018) 78(19):5492–503. doi:  10.1158/0008-5472.Can-18-1367 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Orecchioni M, Ghosheh Y, Pramod AB, Ley K. Macrophage polarization: Different gene signatures in M1(Lps+) vs. classically and M2(Lps-) vs. alternatively activated macrophages. Front Immunol (2019) 10:1084. doi:  10.3389/fimmu.2019.01084 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Agarwal A, Durairajanayagam D, Tatagari S, Esteves SC, Harlev A, Henkel R, et al. Bibliometrics: Tracking research impact by selecting the appropriate metrics. Asian J Androl (2016) 18(2):296–309. doi:  10.4103/1008-682x.171582 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Chen C, Song M. Visualizing a field of research: A methodology of systematic scientometric reviews. PloS One (2019) 14(10):e0223994. doi:  10.1371/journal.pone.0223994 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Chen C. Searching for intellectual turning points: Progressive knowledge domain visualization. Proc Natl Acad Sci U.S.A. (2004) 101 Suppl 1(Suppl 1):5303–10. doi:  10.1073/pnas.0307513100 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Aria M, Cuccurullo C. Bibliometrix: An r-tool for comprehensive science mapping analysis. J Informetrics (2017) 11(4):959–75. doi:  10.1016/j.joi.2017.08.007 [DOI] [Google Scholar]
  • 12. van Eck NJ, Waltman L. Software survey: Vosviewer, a computer program for bibliometric mapping. Scientometrics (2010) 84(2):523–38. doi:  10.1007/s11192-009-0146-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Chen C. Science mapping: A systematic review of the literature. J Data Inf Sci (2017) 2(2):1–40. doi:  10.1515/jdis-2017-0006 [DOI] [Google Scholar]
  • 14. Li MO, Wolf N, Raulet DH, Akkari L, Pittet MJ, Rodriguez PC, et al. Innate immune cells in the tumor microenvironment. Cancer Cell (2021) 39(6):725–9. doi:  10.1016/j.ccell.2021.05.016 [DOI] [PubMed] [Google Scholar]
  • 15. Marelli G, Erreni M, Anselmo A, Taverniti V, Guglielmetti S, Mantovani A, et al. Heme-Oxygenase-1 production by intestinal Cx3cr1(+) macrophages helps to resolve inflammation and prevents carcinogenesis. Cancer Res (2017) 77(16):4472–85. doi:  10.1158/0008-5472.Can-16-2501 [DOI] [PubMed] [Google Scholar]
  • 16. Savino B, Caronni N, Anselmo A, Pasqualini F, Borroni EM, Basso G, et al. Erk-dependent downregulation of the atypical chemokine receptor D6 drives tumor aggressiveness in kaposi sarcoma. Cancer Immunol Res (2014) 2(7):679–89. doi:  10.1158/2326-6066.Cir-13-0202 [DOI] [PubMed] [Google Scholar]
  • 17. Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, Rapisarda A, et al. Regulation of the chemokine receptor Cxcr4 by hypoxia. J Exp Med (2003) 198(9):1391–402. doi:  10.1084/jem.20030267 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res (2010) 70(6):2235–44. doi:  10.1158/0008-5472.Can-09-2335 [DOI] [PubMed] [Google Scholar]
  • 19. Belgiovine C, Bello E, Liguori M, Craparotta I, Mannarino L, Paracchini L, et al. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br J Cancer (2017) 117(5):628–38. doi:  10.1038/bjc.2017.205 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol (2004) 25(12):677–86. doi:  10.1016/j.it.2004.09.015 [DOI] [PubMed] [Google Scholar]
  • 21. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat Immunol (2010) 11(10):889–96. doi:  10.1038/ni.1937 [DOI] [PubMed] [Google Scholar]
  • 22. Porta C, Ippolito A, Consonni FM, Carraro L, Celesti G, Correale C, et al. Protumor steering of cancer inflammation by P50 nf-κb enhances colorectal cancer progression. Cancer Immunol Res (2018) 6(5):578–93. doi:  10.1158/2326-6066.Cir-17-0036 [DOI] [PubMed] [Google Scholar]
  • 23. Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (Defective nf-kappab and enhanced irf-3/Stat1 activation). Blood (2006) 107(5):2112–22. doi:  10.1182/blood-2005-01-0428 [DOI] [PubMed] [Google Scholar]
  • 24. Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, et al. P50 nuclear factor-kappab overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res (2006) 66(23):11432–40. doi:  10.1158/0008-5472.Can-06-1867 [DOI] [PubMed] [Google Scholar]
  • 25. Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, et al. Macrophage il-10 blocks Cd8+ t cell-dependent responses to chemotherapy by suppressing il-12 expression in intratumoral dendritic cells. Cancer Cell (2014) 26(5):623–37. doi:  10.1016/j.ccell.2014.09.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, et al. Cd4(+) t cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 16(2):91–102. doi:  10.1016/j.ccr.2009.06.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Shiao SL, Ruffell B, DeNardo DG, Faddegon BA, Park CC, Coussens LM. Th2-polarized Cd4(+) t cells and macrophages limit efficacy of radiotherapy. Cancer Immunol Res (2015) 3(5):518–25. doi:  10.1158/2326-6066.Cir-14-0232 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Fu LQ, Du WL, Cai MH, Yao JY, Zhao YY, Mou XZ. The roles of tumor-associated macrophages in tumor angiogenesis and metastasis. Cell Immunol (2020) 353:104119. doi:  10.1016/j.cellimm.2020.104119 [DOI] [PubMed] [Google Scholar]
  • 29. Larionova I, Kazakova E, Gerashchenko T, Kzhyshkowska J. New angiogenic regulators produced by tams: Perspective for targeting tumor angiogenesis. Cancers (Basel) (2021) 13(13). doi:  10.3390/cancers13133253 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Deryugina EI, Quigley JP. Tumor angiogenesis: Mmp-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biol (2015) 44-46:94–112. doi:  10.1016/j.matbio.2015.04.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Duran CL, Borriello L, Karagiannis GS, Entenberg D, Oktay MH, Condeelis JS. Targeting Tie2 in the tumor microenvironment: From angiogenesis to dissemination. Cancers (Basel) (2021) 13(22). doi:  10.3390/cancers13225730 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Casazza A, Laoui D, Wenes M, Rizzolio S, Bassani N, Mambretti M, et al. Impeding macrophage entry into hypoxic tumor areas by Sema3a/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell (2013) 24(6):695–709. doi:  10.1016/j.ccr.2013.11.007 [DOI] [PubMed] [Google Scholar]
  • 33. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, et al. "Re-educating" tumor-associated macrophages by targeting nf-kappab. J Exp Med (2008) 205(6):1261–8. doi:  10.1084/jem.20080108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. Ikkbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 118(3):285–96. doi:  10.1016/j.cell.2004.07.013 [DOI] [PubMed] [Google Scholar]
  • 35. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, et al. Deletion of Nemo/Ikkgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell (2007) 11(2):119–32. doi:  10.1016/j.ccr.2006.12.016 [DOI] [PubMed] [Google Scholar]
  • 36. La Fleur L, Boura VF, Alexeyenko A, Berglund A, Pontén V, Mattsson JSM, et al. Expression of scavenger receptor marco defines a targetable tumor-associated macrophage subset in non-small cell lung cancer. Int J Cancer (2018) 143(7):1741–52. doi:  10.1002/ijc.31545 [DOI] [PubMed] [Google Scholar]
  • 37. Georgoudaki AM, Prokopec KE, Boura VF, Hellqvist E, Sohn S, Östling J, et al. Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep (2016) 15(9):2000–11. doi:  10.1016/j.celrep.2016.04.084 [DOI] [PubMed] [Google Scholar]
  • 38. Li X, Shao C, Shi Y, Han W. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol (2018) 11(1):31. doi:  10.1186/s13045-018-0578-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. Pd-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature (2017) 545(7655):495–9. doi:  10.1038/nature22396 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Yang D, Yang L, Cai J, Li H, Xing Z, Hou Y. Phosphoinositide 3-Kinase/Akt and its related signaling pathways in the regulation of tumor-associated macrophages polarization. Mol Cell Biochem (2022) 477(10):2469–80. doi:  10.1007/s11010-022-04461-w [DOI] [PubMed] [Google Scholar]
  • 41. De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, et al. Overcoming resistance to checkpoint blockade therapy by targeting Pi3kγ in myeloid cells. Nature (2016) 539(7629):443–7. doi:  10.1038/nature20554 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Kaneda MM, Cappello P, Nguyen AV, Ralainirina N, Hardamon CR, Foubert P, et al. Macrophage Pi3kγ drives pancreatic ductal adenocarcinoma progression. Cancer Discovery (2016) 6(8):870–85. doi:  10.1158/2159-8290.Cd-15-1346 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Han MG, Jang BS, Kang MH, Na D, Kim IA. Pi3kγδ inhibitor plus radiation enhances the antitumour immune effect of pd-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model. Eur J Cancer (2021) 157:450–63. doi:  10.1016/j.ejca.2021.08.029 [DOI] [PubMed] [Google Scholar]
  • 44. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting tumor-associated macrophages with anti-Csf-1r antibody reveals a strategy for cancer therapy. Cancer Cell (2014) 25(6):846–59. doi:  10.1016/j.ccr.2014.05.016 [DOI] [PubMed] [Google Scholar]
  • 45. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. Csf-1r inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 19(10):1264–72. doi:  10.1038/nm.3337 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Trac N, Chen LY, Zhang A, Liao CP, Poon C, Wang J, et al. Ccr2-targeted micelles for anti-cancer peptide delivery and immune stimulation. J Control Release (2021) 329:614–23. doi:  10.1016/j.jconrel.2020.09.054 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Liu Y, Wang J, Zhang J, Marbach S, Xu W, Zhu L. Targeting tumor-associated macrophages by Mmp2-sensitive apoptotic body-mimicking nanoparticles. ACS Appl Mater Interfaces (2020) 12(47):52402–14. doi:  10.1021/acsami.0c15983 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Zhang Y, Chen Y, Li J, Zhu X, Liu Y, Wang X, et al. Development of toll-like receptor agonist-loaded nanoparticles as precision immunotherapy for reprogramming tumor-associated macrophages. ACS Appl Mater Interfaces (2021) 13(21):24442–52. doi:  10.1021/acsami.1c01453 [DOI] [PubMed] [Google Scholar]
  • 49. Nie W, Wu G, Zhang J, Huang LL, Ding J, Jiang A, et al. Responsive exosome nano-bioconjugates for synergistic cancer therapy. Angew Chem Int Ed Engl (2020) 59(5):2018–22. doi:  10.1002/anie.201912524 [DOI] [PubMed] [Google Scholar]
  • 50. Li H, Somiya M, Kuroda S. Enhancing antibody-dependent cellular phagocytosis by re-education of tumor-associated macrophages with resiquimod-encapsulated liposomes. Biomaterials (2021) 268:120601. doi:  10.1016/j.biomaterials.2020.120601 [DOI] [PubMed] [Google Scholar]
  • 51. Xia Y, Rao L, Yao H, Wang Z, Ning P, Chen X. Engineering macrophages for cancer immunotherapy and drug delivery. Adv Mater (2020) 32(40):e2002054. doi:  10.1002/adma.202002054 [DOI] [PubMed] [Google Scholar]
  • 52. Cheng Y, Song S, Wu P, Lyu B, Qin M, Sun Y, et al. Tumor associated macrophages and tams-based anti-tumor nanomedicines. Adv Healthc Mater (2021) 10(18):e2100590. doi:  10.1002/adhm.202100590 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES